Pharmacy coverage changes
Summary
Effective 10/1/2026, Yesintek (ustekinumab-kfce) will be removed from formulary and become non-covered for Tufts Health RITogether plans. Starjemza (ustekinumab-hmny), the preferred ustekinumab biosimilar, will replace it and require prior authorization. New starts and new members will have coverage reviewed under different medical necessity guidelines.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.